

Substitute for form 1449/PTO			<b><i>Complete if Known</i></b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>			Application Number	09/900,364
			Filing Date	July 5, 2001
			First Named Inventor	Paul D. van Poelje
			Art Unit	1617
			Examiner Name	Leonard M. Williams
Sheet	1	of	10	Attorney Docket Number
U.S. PATENT DOCUMENTS				

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if Known)			
1.	3,551,422		12-29-1970	Tesoro, et al.	All
2.	3,650,670		03-01-1972	Tesoro, et al.	All
3.	3,657,282		04-18-1972	Christensen, et al.	All
4.	3,822,296		07-02-1974	Christensen, et al.	All
5.	3,931,206		01-06-1976	Bowler, et al.	All
6.	4,000,305		12-26-1976	Bowler, et al.	All
7.	4,046,841		09-06-1977	Foster, et al.	All
8.	4,092,323		05-30-1978	Foster, et al.	All
9.	4,587,256		05-06-1986	Hasler, et al.	All
10.	4,746,654		05-24-1988	Breliere, et al.	All
11.	4,728,739		03-01-1988	Kees, et al.	All
12.	4,791,125		12-13-1988	Clark, D.	All
13.	4,876,248		10-24-1989	Breliere, et al.	All
14.	4,939,130		07-01-1990	Jaeggi, et al.	All
15.	5,116,919		05-01-1992	Buzinkai, et al.	All
16.	5,133,972		07-28-1992	Ferrini, et al.	All
17.	5,142,000		08-01-1992	Wheland, et al.	All
18.	5,236,941		08-17-1993	Zask, et al.	All
19.	5,457,109		10-10-1995	Antonucci, et al.	All
20.	5,468,762		11-21-1995	Malamas, et al.	All
21.	5,478,853		12-26-1995	Regnier, et al.	All
22.	5,532,256		07-02-1996	Malamas, et al.	All
23.	5,550,276		08-27-1996	Wirth, et al.	All
24.	5,610,210		03-11-1997	Holderbaum, et al.	All
25.	5,728,650		03-01-1998	Fisher, et al.	All
26.	5,731,299		03-01-1998	Ebetino, et al.	All
27.	5,798,340		08-25-1998	Bischofberger, et al.	All
28.	5,925,656		07-20-1999	Kallam, et al.	All
29.	5,958,904		09-28-1999	Cordi, et al.	All
30.	5,985,858		11-16-1999	Miyata et al.	All
31.	6,001,862		12-14-1999	Maeda, et al.	All
32.	6,028,052		02-22-2000	Heyman, et al.	All
33.	6,110,903		08-29-2000	Kasibhatla, et al.	All
34.	6,200,998		03-13-2001	Sahoo, et al.	All
35.	6,284,672		09-01-2001	Yu, et al.	All
36.	6,008,237		12-01-1999	Sahoo, et al.	All
37.	6,030,990		02-29-2000	Maeda, et al.	All

Examiner Signature	Date Considered
--------------------	-----------------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Classification is given by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed forms to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			<i><b>Complete if Known</b></i>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>			Application Number	09/900,364	
Sheet	2	of	10	Filing Date	July 5, 2001
				First Named Inventor	Paul D. van Poelje
				Art Unit	1617
				Examiner Name	Leonard M. Williams
				Attorney Docket Number	MET-037CXT
	38.	6,037,335 B1	03-14-2000	Takashima, et al.	All
	39.	6,054,587	04-01-2000	Reddy, et al.	All
	40.	6,284,748 B1	08-01-2001	Dang, et al.	All
	41.	6,294,672 B1	09-01-2001	Reddy, et al.	All
	42.	2003/0073728	04-17-2003	Van Poelje, et al.	All

<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document <small>Country Code* Number* Kind Code* (if known)</small>	Publication Date <small>MM-DD-YYYY</small>	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	43.	AU 654899B B2	09-09-1993	De Nanteuil, et al.	All
	44.	DE 195 01 843 A1	6-20-1996	Vass, et al.	All
	45.	DE 40 29 444 A1	03-28-1991	Maier, et al.	All
	46.	EP 0 033 195 A1	08-05-1981	Gacek, M.	All
	47.	EP 0 034 480 A2	08-26-1981	Gigg, et al.	All
	48.	EP 0 091 761 B1	11-19-1987	Kawamatsu, et al.	All
	49.	EP 0 177 353 A2	09-04-1986	Meguro, et al.	All
	50.	EP 0 186 405 A2	02-07-1986	Benedict, et al.	All
	51.	EP 0 230 068 A2	07-29-1987	Benedict, et al.	All
	52.	EP 0 243 173 B1	06-26-1991	Oku, et al.	All
	53.	EP 0 283 035 A1	09-21-1988	Iijima, et al.	All
	54.	EP 0 354 322 A2	02-14-1990	DeVries, et al.	All
	55.	EP 0 506 273 A2	09-30-1992	Arita, et al.	All
	56.	EP 0 528 760 A1	02-24-1993	Hayakawa, et al.	All
	57.	EP 0 543 662 A2	05-26-1993	Fujita, et al.	All
	58.	EP 0 559 079 A1	09-08-1993	Phan, et al.	All
	59.	EP 0 603 419 A1	06-29-1994	Shibata, et al.	All
	60.	EP 0 620 227 A1	10-19-1994	Yoshikawa, et al.	All
	61.	EP 0 636 630 A1	02-01-1995	Norciini, et al.	All
	62.	EP 0 708 098 A1	04-24-1996	Yanagisawa, et al.	All
	63.	EP 0 745 600 A1	12-04-1996	Fujita, et al.	All
	64.	EP 0 787 727 A1	08-06-1997	Nagao, et al.	All
	65.	EP 0 861 666 A2	09-02-1998	Ikeda, et al.	All
	66.	EP 0 489 663 A1	06-10-1992	Miyaoka, et al.	All
	67.	EP 0 353 969 A1	02-07-1990	Wheland, et al.	All
	68.	GB 1343022	01-09-1974	British Oxygen CO. LTD.	All

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional) \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.\* Enter Office that issued the document by the two-letter code (MPO=Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WMO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including time for reviewing the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form, or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9799 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>			
Sheet		3	of 10
		Attorney Docket Number	
<i>Complete if Known</i>			
Application Number		09/900,364	
Filing Date		July 5, 2001	
First Named Inventor		Paul D. van Poelje	
Art Unit		1617	
Examiner Name		Leonard M. Williams	

69.	GB 2271113 A	04-06-1994	Ichiro, et al.	All
70.	JP 07-002852 A2 (abstract only)	01-06-1995	Yoshioka, et al.	All
71.	JP 6-306089 A2 (abstract only)	01-11-1994	Shoji, et al.	All
72.	JP 09-048770 (abstract only)	05-30-1996	Sankyo, Co., Ltd.	All
73.	WO 90/09163	08-23-1990	Gensia Pharma	All
74.	WO 91/19721	12-01-1991	Glazier, A.	All
75.	WO 92/11269 A1	07-09-1992	Pohjala, et al.	All
76.	WO 92/12985 A1	08-06-1992	Thorn, et al.	All
77.	WO 92/19629 A1	11-12-1992	Mori, et al.	All
78.	WO 93/14081	07-22-1993	Adams, et al.	All
79.	WO 93/15610 A1	08-19-1993	Cox, et al.	All
80.	WO 94 07867	04-14-1994	Mylari, et al.	All
81.	WO 95/026347 A1	10-05-1995	Ohara, et al.	All
82.	WO 95/07920	03-23-1995	Bischofberger, et al.	All
83.	WO 95/14385 A1	06-01-1995	Lindell, et al.	All
84.	WO 96/11196 A1	04-18-1996	Ohara, et al.	All
85.	WO 96/26207 A1	08-29-1996	Ohara, et al.	All
86.	WO 96/39401 A1	12-12-1996	Inman, et al.	All
87.	WO 97/10819	03-27-1997	Heyman, et al.	All
88.	WO 97/37688 A2	10-16-1997	Tamura, et al.	All
89.	WO 97/40051 A1	10-30-1997	Takatani, et al.	All
90.	WO 98/04528	02-05-1998	Schmidt, et al.	All

<b>NON PATENT LITERATURE DOCUMENTS</b>				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published		
	91.	Alimov, et al. "Preparation of amides on N-Phosphorylated amino carboxylic acids", Online, Chemical abstracts, Columbus, OH, April 25, 2003.		
	92.	Amri, et al. "Regulation of adipose cell differentiation. I. Fatty acids are inducers of the aP2 gene expression", J. Lipid Res., pp. 1449-1456, 1991.		
Examiner Signature		Date Considered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. \*Enter Office that issued the document by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you have spent to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO			<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>			Application Number	09/900,364
			Filing Date	July 5, 2001
			First Named Inventor	Paul D. van Poelje
			Art Unit	1617
			Examiner Name	Leonard M. Williams
Sheet	4	of	10	Attorney Docket Number
MET-037CXCT				

	93.	Arcoria, et al. "Reactions of Triethyl Phosphite with 2-Haloacetyl-furan, -thiophene, -pyrrole and -N-methylpyrrole (1)", <i>J. Het. Chem.</i> , Vol. 12, pp. 215-218, 1975.	
	94.	Ayral-Kaloustian, et al. "Synthesis of Partially-Protected D-fructofuranoses and D-fructose-6-phosphates" <i>Carbohydrate Research</i> , Vol. 214, pp. 187-192, Elsevier Science Publishers B.V., 1991.	
	95.	Baudy, et al. "Potent Quinoxaline-Spaced Phosphono α-Amino Acids of the AP-6 Type as Competitive NMDA Antagonists Synthesis and Biological Evaluation", <i>J. Med. Chem.</i> , Vol. 36, No. 3, pp. 331-342, 1992.	
	96.	Banker (Modern Pharmaceutics) Banker, G.S. et al. "Modern Pharmaceutics", 3 <sup>rd</sup> Edition, Marcel Dekker, New York, 1996, p. 451.	
	97.	Benzaria, et al. "Synthesis in Vitro Antiviral Evaluation and Stability Studies of Bis(S-acyl-2-thioethyl) Ester Derivatives of 9-(2-(Phosphonomethoxy) ethyl)adenine (PMEA) as Potent PMEA Prodrugs with Improved Oral Bioavailability", <i>J. Med. Chem.</i> , Vol. 39, pp. 4958-4965, 1996.	
	98.	Brown, et al. "A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-γ reverses the diabetic phenotype of the zucker diabetic fatty rat", <i>Diabetes</i> , Vol. 48, pp. 1415-1424, 1999.	
	99.	Burke, et al. "Stereoselective Syntheses of the Rhizoxin C(1)-C(9) and C(12)--C(26) Subunits", <i>Tetrahedron Letters</i> , Vol. 39, pp. 2239-2242, 1998.	
	100.	Clark, et al. "Substituted dihydrobenzopyran and dihydrobenzofuran thiazolidine-2,4-diones as hypoglycemic agents", <i>J. Med. Chem.</i> , Vol. 34, pp. 319-325, 1991.	
	101.	Corsano, et al. "A New Synthesis of Unsaturated Phosphonates (*)(**)", <i>Gazzetta Chimica Italiana</i> , Vol. 119, pp. 597-599, 1989.	
	102.	De Lombaert, et al. "N-Phosphonomethyl Dipeptides and Their Phosphonate Prodrugs, a New Generation of Neutral Endopeptidase (NEP, EC 3.4.24.11) Inhibitors", <i>J. Med. Chem.</i> , pp. 498-511, 1994.	
	103.	Dizieree, et al. "A New Simple Method for the Synthesis of 1-Alkynylphosphonates using (EtO) <sub>2</sub> P(O)CCl <sub>3</sub> as Precursor", <i>Tetrahedron Letters</i> Vol. 37, No. 11, pp. 1783-1786, 1996	

Examiner Signature	Date Considered	
--------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document by the two-letter code (WIPO Standard ST 3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. \*Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is reduced to practice by 37 CFR 1.87 and 1.90. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO in the PTO process) an application. Confidentiality is guaranteed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-787-9199) and select option 2.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	09/900,364
				Filing Date	July 5, 2001
				First Named Inventor	Paul D. van Poelje
				Art Unit	1617
				Examiner Name	Leonard M. Williams
Sheet	5	of	10	Attorney Docket Number	MET-037CXT

	104.	Ebetino, et al. "A Stereoselective Process for the Preparation of Novel Phosphonoalkylphosphinates", Journal of Organometallic Chemistry, Vol. 529, pp. 135-142, 1997.	
	105.	Farquhar, et al. "Biologically Reversible Phosphate-Protective Groups", Journal of Pharmaceutical Sciences, Vol. 72, pp. 324-325, 1983.	
	106.	Foley, et al. "Rationale and Application of Fatty Acid Oxidation Inhibitors in Treatment of Diabetes Mellitus", Diabetes Care, Vol. 15, No. 6, pp. 773-784, 1992.	
	107.	Folli, et al. "Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels", J. Clin. Invest., Vol. 100, No. 9, pp. 2158-2169, 1997.	
	108.	Franchetti, et al. "Acyclic Nucleotides Related to Clitocine: Synthesis and Anti-HIV Activity", Nucleosides & Nucleotides, Vol. 14, No. 3-5, pp. 607-610, 1995.	
	109.	Freeman, et al. "Prodrug Design for Phosphates and Phosphonates", Progress in Medicinal Chemistry, p. 34, 1997.	
	110.	Fujita, et al. "Organic Synthesis Utilizing Thiazolidine and The Related Heterocycles", Heterocycles, Vol. 21, No. 1, pp. 41-60, 1984.	
	111.	Fujiwara, et al. "Characterization of new oral antidiabetic agent CS-045: Studies in KK and ob/ob mice and zucker fatty rats", Diabetes, Vol. 37, pp. 1549-1558, 1988.	
	112.	Garuti, et al. "Synthesis and Biological Evaluation of Some New Phosphates", Pharmazie, Vol. 47, pp. 295-297, 1992.	
	113.	Gastaldelli, et al. "Influence of Obesity and Type 2 Diabetes on Gluconeogenesis and Glucose Output in Humans", Diabetes, Vol. 49, pp. 1367-1373, 2000.	
	114.	Gerich, et al. "Matching Treatment to Pathophysiology in Type 2 Diabetes", Clinical Therapeutics, Vol. 23, No. 5, pp. 646-659, 2001.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional) \*See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. \*Enter Office that issued the document by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including time for reviewing instructions, searching existing data sources, gathering and maintaining the needed information, and completing and reviewing the collected application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	09/900,364
				Filing Date	July 5, 2001
				First Named Inventor	Paul D. van Poelje
				Art Unit	1617
				Examiner Name	Leonard M. Williams
Sheet	6	of	10	Attorney Docket Number	MET-037CXCT

	115.	Glucksmann, et al. "Novel mutations and a mutational hotspot in the MODY3 gene", Diabetes, Vol. 46, pp. 1081-1086, 1997.	
	116.	Gohda, et al. "Theoretical Evidence of the Existence of a Diazafulvene Intermediate in the reaction Pathway of Imidazoleglycerol Phosphate Dehydratase: Design of Novel and Potent Heterocycle Structure for the Inhibitor on the Basis of the Electronic Structure-Activity Relationship Study", Biochimica et Biophysica Acta, Vol. 1385, pp. 107-114, 1998.	
	117.	Grimaldi, et al. "Induction of a P2 gene expression by nonmetabolized long-chain fatty acids", Proc. Natl. Sci. USA, Vol. 89, pp. 10930-10934, 1992.	
	118.	Groop, "Sulfonylureas In NIDDM", Diabetes Care, Vol. 15, No. 6, pp. 737-754, 1992.	
	119.	Harada, et al. "Resolution of 1,3-Alkanediois via Chiral Spiroketals Derived from £Menthone" Tetrahedron Letters, Vol. 28, No. 41, pp. 4843-4846, 1987.	
	120.	Holst, et al. "Inhibition of the Activity of Dipeptidyl-Peptidase IV as a Treatment for Type 2 Diabetes", Diabetes, Vol. 47, pp. 1663-1670, 1998.	
	121.	Hoover, et al. "Indole-2-Carboxamide Inhibitor of Human Liver Glycogen Phosphorylase", J. Med. Chem., Vol. 41, pp. 2934-2938, 1998.	
	122.	Hulin, et al. "Novel thiazolidine-2,4-diones as potent euglycemic agents", J. Med. Chem., Vol. 35, pp. 1853-1864, 1992.	
	123.	Hundal, et al. "Mechanism by Which Metformin Reduces Glucose Production in Type 2 Diabetes", Diabetes, Vol. 49, pp. 2053-2069, 2000.	
	124.	Inzucchi, S.E. et al. "Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus", N.E. Journal of Medicine, Vol. 338, No. 13, pp. 867-872, Massachusetts Medical Society, March 26, 1998.	
	125.	Khamnei, et al. "Neighboring Group Catalysis in the Design of Nucleotide Prodrugs", J. Med. Chem., Vol. 39, pp. 4109-4115, 1996.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional) \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete. Estimated burden does not include time spent preparing the related application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form, or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-785-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	09/900,364
				Filing Date	July 5, 2001
				First Named Inventor	Paul D. van Poelje
				Art Unit	1617
				Examiner Name	Leonard M. Williams
Sheet	7	of	10	Attorney Docket Number	MET-037CXLT

	126.	Kolyamshin, et al. "Phosphorus-Containing Small Rings. VII* Amino Phosphorus Esters with a 2, 2-Dichlorocycle-o-propyl Fragment", Russian Journal of Gen. Chem., Vol. 63, No. 1, pp. 29-33, 1993.	
	127.	Lehmann, et al. "An Antidiabetic Thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ(PPAR γ)", J. Biol. Chem., Vol. 270, No. 22, pp. 12953-12956, 1995.	
	128.	Maier, et al. "Organic Phosphorus Compounds 97.* Synthesis and Properties of 1-Amino-2-Aryl-and-2-Pyridyl-Ethylphosphonic Acids and Derivates", Phosphorus, Sulfur and Silicone, Vol. 62, pp. 15-27, 1991.	
	129.	Maruszewska-Wieczorowska, et al. "Synthesis of 2-(Pyridyl)ethylphosphonic Acids and Esters", Chemical Abstracts, Vol. 23, pp. 1886-1889, 1958.	
	130.	Maruszewska-Wieczorowska, et al. "Alkyl and Alkenyl Pyridines, Part VII. 3-(2'-Pyridyl)-Propylphosphonic Acid Alkilo I Alkenylopirydny, VII. Kwas 3-(2'-Pirydyl)-Propylofostanowy", Roczniki Chemii Ann Soc. Chim. Polonorum, Vol. 37, p. 1315, 1963.	
	131.	Mathisen, et al. "The effect of pioglitazone on glucose control and lipid profile in patients with type 2 diabetes", Diabetes, Vol. 48, Suppl. 1, 0441, 1998.	
	132.	Menard, et al. "Synthesis and Preliminary Evaluation of Chelating Resins Containing a-amoalkylphosphonic Groups", Reactive Polymers, Vol. 32, pp. 201-212, 1994.	
	133.	Mikhailuchenko, et al. "2-Chloro-1-(Diethoxyphosphinyl)Ethyl Isocyanate", Institute of Organic Chemistry, Vol. 47, No. 10, pp. 2011-2012, October 1977.	
	134.	Mikityuk, et al. "C-Acylation of Diazomethane with (Diethoxy-phosphinyl)Acetyl Chloride", UDC, Vol. 57, No. 7, pp. 1669-1670, July 1987.	
	135.	Mitchell, et al. "Bioreversible Protective for the Phospho Group: Bioactivation of the Di(4-acyloxybenzyl) and Mono(4-acyloxybenzyl) Phosphoesters of Methylphosphonate and Phosphonoacetate", J. Chem. Soc. Perkin Trans., pp. 2345-2353, 1992.	
	136.	Mori, et al. "Synthesis of Inhibitors of Imidazole Glycerol Phosphate Dehydratase", J. Am Chem Soc., Vol. 117, pp. 4411-4412, 1995.	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. \*Enter Office that issued the document by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) a patent application. Collection of this information by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9799 (1-800-785-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			<i>Complete if Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>			Application Number	09/900,364
			Filing Date	July 5, 2001
			First Named Inventor	Paul D. van Poelje
			Art Unit	1617
			Examiner Name	Leonard M. Williams
Sheet	8	of	10	Attorney Docket Number
MET-037CXCT				

	137.	Morita, et al. "Synthesis and Antihypertensive Activities of 1, 4-Dihydropyridine-5-phosphonate Derivatives." Chem. Pharm Bull, Vol. 35, No. 9, pp. 3898-3904, 1987.		
	138.	O'Donnell, et al. "Preparation of an α-Aminophosphonate Cation Equivalent and its Reaction with organoboranes", Tetrahedron Letters, Vol. 35, pp. 6421-6424, 1994.		
	139.	Palacios, et al. "A "One Pot" Synthesis of Polysubstituted Pyridines from Metallated Alkylphosphonates, Nitriles and a, β-Unsaturated Ketones", Tetrahedron Letters, Vol. 37, No. 26, pp. 4577-4580, 1996.		
	140.	Palacios, et al. "A New and Efficient Strategy for the Preparation of 1, 5, 2-Diazaphosphorines from Primary β-Enaminophosphonates", Tetrahedron Lett., pp. 3091-3104, 1999.		
	141.	Palacios, et al. "A Simple and Efficient Strategy for the Preparation of 5-Phosphorylated Imidazol.-2-ones from Primary β-Enaminophosphonates", Tetrahedron, Vol. 54, pp. 2281-2288, 1998.		
	142.	Patel, et al. "Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: A twelve-week, randomized, placebo-controlled study", Diabetes, Obesity and Metabolism, Vol. 1, pp. 165-172, 1999.		
	143.	Puech, et al. "Intracellular delivery of Nucleoside monophosphates through a reductase-mediated activation process", Antiviral Research Vol. 22, pp. 155-174, 1993.		
	144.	Reznick, et al. "Synthesis and Properties of Pyrimidinylalkiphosphonic Acids. 8. Interaction of Some Hydroxypyrimidines With Formaldehyde and Some Phosphorus (III) Derivatives", Organometallics, Vol. 83, p. 523, 1975.		
	145.	Reznick, et al. "Synthesis and Properties of Pyrimidinylalkiphosphonic Acids., 6. Reaction of some Hydroxypyrimidines with Diethyl 3-Chlorophosphonate", Chem Abs, Vol. 79, p. 380, 1973.		
	146.	Rizzi, et al. "PPN-type Nitrones: Preparation and use of a new series of β-phosphorylated spin-trapping agents", J. Chem. Soc. Perkins Trans., Vol. 2, pp. 2513-2518, 1997.		
	147.	Saltiel, et al. "Thiazolidinediones in the treatment of insulin resistance and type II diabetes", Diabetes, Vol. 45, pp. 1661-1669, 1996.		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds of Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. \*Enter Office that issued the document by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments or suggestions on the burden estimate or any suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-787-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
				Application Number	09/900,364
				Filing Date	July 5, 2001
				First Named Inventor	Paul D. van Poelje
				Art Unit	1617
				Examiner Name	Leonard M. Williams
Sheet	9	of	10	Attorney Docket Number	MET-037CXCT

	148.	Schmitz-Peiffer, et al. "Reversal of chronic alterations of skeletal muscle protein kinase C from fat-fed rats by BRL-49653", Am. J. Physiol., Vol. 273, pp. E915-E921, 1997.	
	149.	Serafinowska, et al. "Synthesis and in Vivo Evaluation of Prodrugs of 9-[2-(Phosphonomethoxy)ethoxy]adenine", J. Med. Chem., Vol. 38, pp. 1372-1379, 1995.	
	150.	Siddiqui, et al. "The Presence of Substituents on the Aryl Moiety of the Aryl Phosphoramidate Derivative of d4T Enhances Anti-HIV Efficacy in Cell Culture: A Structure--Activity Relationship", J. Med. Chem., Vol. 42, pp. 393-399, 1999.	
	151.	Smith, et al. "Synthesis and Biological Activity of Novel Cephalosporins Containing a (Z)-Vinyl Dimethylphosphonate Group", Vol. 48, No. 1, pp. 73-82, 1995.	
	152.	Starrett, et al. "Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy)ethyl]adenine (PNEA)", J. Med. Chem., Vol. 37, No. 12, pp. 1857-1864, 1994.	
	153.	Szczepaniak, et al. "Phosphoroorganic Complexones, Part VIII*. N-(Picolylamino)Isopropylphosphonic Acids", Polish J. of Chem., Vol. 52, pp. 721-726, 1978.	
	154.	Tontonoz, et al. "mPPARY2: Tissue specific regulator of an adipocyte enhancer", Gene and Development, Vol. 8, pp. 1224-1234, 1994.	
	155.	Tontonoz, et al. "Stimulation of Adipogenesis in fibroblasts by PPARY2, a lipid-activated transcription factor", Cell, Vol. 79, pp. 1147-1156, 1994.	
	156.	Valiquett, et al., "Troglitazone dose-response study in patients with NIDDM", Diabetes, Vol. 44, Suppl. 1, p. 406, 1995.	
	157.	Van Poelje, et al. "Combination Therapy with Pioglitazone and a Fructose 1, 6-Bisphosphatase Inhibitor (MB06322: CS-917) Improves Glycaemic Control and Lactate Homeostasis in Male Zucker Diabetic Fatty (ZDF) Rats" poster presented at the European Association for the Study of Diabetes (EASD), Copenhagen, Denmark, September 14-17, 2006.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and maintaining the collection. Any comments on the amount of time you estimate to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-8799 (1-800-785-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	09/900,364
Sheet	10	of	10	Filing Date	July 5, 2001
				First Named Inventor	Paul D. van Poelje
				Art Unit	1617
				Examiner Name	Leonard M. Williams
				Attorney Docket Number	MET-037CXT

158.	Willson, et al. "The Structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones", J. Med. Chem., Vol. 39, pp. 665-668, 1996.	
159.	Wolff, Manfred E. "Burger's Medicinal Chemistry and Drug Discovery", 5 <sup>th</sup> Edition, Vol. 1, John Wiley & Sons, 1995, pp. 975-977.	
160.	Zask, et al. "Synthesis and antihyperglycemic activity of novel 5-(naphthalenylsulfonyl)-2,4-thiazolidinediones", J. Med. Chem., Vol. 33, pp. 1418-1423, 1990.	
161.	Zhao, et al. "Synthesis of Trans-4-Alkenyl Oxazoles", Tetrahedron Letters, Vol. 32, No. 13, pp. 1609-1612, 1991.	
162.	"An Update on Type 2 Diabetes in Youth From the National Diabetes Education Program", Pediatrics, 2004, Vol. 114, pp. 259-263.	

Examiner Signature	/ Yong Chong /	Date Considered	4/03/09
-----------------------	----------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional) \*See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

The collection of information required by 37 CFR 1.87 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, reviewing, and completing the required application forms to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.